@soicfinance Most were bullish on #SeQuent a day before the annual results the other week. Most would have left the train in next few quarters due to ESOP led margin compression on P&L. Playing long innings like Rahul Dravid is not same as watching him play :)

@RemindMe_OfThis in 200 days

Most Indian businesses are locally competitive. You take them outside India, and they struggle. Very few businesses (IT, Pharma/API, Chemicals/CDMO) are fit to compete and beat global competition. These rare gems tend to survive over long time periods and thrive over all cycles.

Only one Indian company is making the country pound in the US when it comes to Biologics #Biocon @Bioconlimited 👏👏

Company floated and nurtured by a women despite all the gender biases. How can the gents be beaten by a lady?

Monishaaa, ‘Bio-refineries’ bolo beta…
This ‘Sugar Mills’ is just too middle class!

Biosciences is the space to track and follow globally. Sector offers extra large opportunity landscape. Shared the full thesis in that April webinar. Convinced that 🧬 will throw many big compounders in next few years.

#Fermentation #Biotechnology

While the healthcare sector remains a good investment option, it’s one where popular investing beliefs may not work, according to Aditya Khemka.

Watch: https://t.co/sXF22eqmcy

Catch all #BQEdge videos here: https://t.co/KP4BpmUgCS

Thread on Glenmark Life Science IPO 27 July 🧵:

Glenmark Life Science (GLS) is the wholly-owned subsidiary of Glenmark Pharmaceuticals Ltd;

In 2001-02, GLS launched the API manufacturing business; Currently, the company has two key business verticals: namely API and CDMO;

1/25

GLS is a leading developer and manufacturer of select high-value, non-commoditized APIs in chronic therapeutic areas, including CVS, CNS, pain, and diabetes;

As of FY21, API and CDMO contributed ~90.6 & 8.1% to GLS revenues respectively;

2/25

The company works with 16 of the top 20 generic pharma companies in the world and as of 31st May 2021, they have registered ~403 DMFs globally;

From the IPO proceeds, GLS will be using ~Rs 8bn as repayment of an outstanding purchase agreement to the promoter-

3/25

-for the spin-off of the API business. The company has also envisaged using Rs 1.53bn as capital expenditure;

This includes a new multi-usage facility, which will mainly focus on the company’s CDMO business aspiration from 4QFY23.

4/25

Key growth drivers for the Indian API industry:

👉India is on par with other countries in terms of technological capabilities and process efficiency;

👉The costs are very low in India: Domestic pharmaceutical facilities cost only 2/5th of what it costs to set up and-

5/25

@VXP95 Ok. Tyche Industries, Panacea Biotech and Beta drugs. 3 of them🙏🙏

A good read on Monoclonal antibodies (mAbs) and their potential. @unseenvalue @punitbansal14 Would you like to add something on the future of mAbs in pharma industry.